Fig. 3

Antisteatotic effect and hyperinsulinemic-euglycemic clamp test. a, b Effect of OPC-163493 dosing with mixed chow on plasma (a) and hepatic (b) triglyceride (TG) in male ob/ob mice. Data represent mean ± SE (control group: n = 7, other groups: n = 8). No significant difference was found in plasma TG using a two-tailed Williams’ test. A significant difference was found in hepatic TG between control and 0.02% OPC treatment groups using a two-tailed Williams’ test (^∗P < 0.05). Control chow and OPC-163493 admixed chow were fed to each animal group for 10 weeks from the age of 8 weeks. c, d Effect of OPC-163493 on fasting blood glucose (c) and plasma insulin (d) levels in HFD SD Rats. Data represent mean ± SE (n = 18). Significant efficacy was found in the 4 mg kg⁻¹ day⁻¹ OPC-163493-treated groups in blood glucose but not in plasma insulin (^∗P < 0.05 OPC vs. vehicle group by Dunnett’s test). e Effect of OPC-163493 on hepatic lipids in HFD SD Rats. Data represent mean ± SE (n = 18). ^∗P < 0.05, ^∗∗P < 0.01 OPC vs. vehicle group by Dunnett’s test. Black bar, control; gray bar, 2 mg kg⁻¹ day⁻¹; silver bar, 4 mg kg⁻¹ day⁻¹. SD rats were fed with 60 kcal% fat chow for 2 weeks from the age of 10 weeks and the prefeeding was followed by 2-week oral treatment with OPC-163493 during a continued HFD. f Hyperinsulinemic-euglycemic clamp test. Male ZDF(M) rats were fed ad libitum with 0.04% OPC-163493 mixed chow or control chow for 3 weeks from the age of 7 weeks. Data represent mean ± SE (n = 12). Significant differences between the control and OPC-163493 treatment groups were found in basal HGP and Rd (^∗P < 0.05, unpaired t test). Black bar, control; gray bar, OPC-163493